Overview

• The Berufsverband der Kinder- und Jugendärzte (BVKJ) criticizes both the government and insurance companies for not ensuring timely RSV vaccinations for infants.
• High demand and manufacturing delays have led to long waiting lists for the Nirsevimab (Beyfortus) antibody, recommended for newborns and infants.
• Sanofi, the vaccine manufacturer, is attempting to meet demand by sourcing doses from France, Spain, and the USA.
• Pediatricians predict overwhelmed children's hospitals this winter due to RSV and existing structural healthcare issues.
• Concerns are growing about the impact of hospital reforms, which could reduce the number of pediatric beds available.